Ken Blount

Company: Rebiotix Inc., a Ferring Company

Job title: Chief Scientific Officer

Seminars:

Clinical Update on C. diff Candidate RBX2660 11:00 am

Discussing the pivotal Phase 3 trial results of RBX2660, demonstrating its superior efficacy in reducing recurrence of Clostridioides Difficile Infection (CDI) Explore the significance of FDA approval and breakthrough therapy designation for RBX2660, and its impact on accelerating the development and availability of this microbiome-based therapeutic Future Directions and Applications: Examine the potential expansion of…Read more

day: Conference Day One, Track One, AM

Pioneering the Future of Microbiome Therapeutics: Assessing Clinical Progress & Outlining Market Opportunities 8:00 am

Evaluating clinical progress by analysing existing approvals and late-stage clinical trial candidates Unlocking new market opportunities in oncology, women’s health, and metabolic disorders while navigating pharma investment trends Assessing the current progress of incorporating advanced technologies like AI-driven microbiome analysis, synthetic biology, and scalable  manufacturing to accelerate innovationRead more

day: Conference Day One - 7am to 10am

Roundtable: Advancing Microbiome Therapeutics: Insights from the MTIG and EMIH Collaboration 8:00 am

How can harmonized regulatory frameworks benefit microbiome therapeutics across different regions, and what specific steps can be taken to achieve this harmonization? What innovative strategies can be employed to accelerate the development of microbiome-based therapies through international collaboration, and how can these strategies be effectively implemented? How can expanding access to microbiome therapies benefit the…Read more

day: Conference Day Two, 7:30 - 10:00